PBYIMEDIUM SIGNALFINANCIAL10-K

PBYI significantly strengthened its balance sheet by reducing total debt by two-thirds while maintaining operational profitability and growing operating income.

The company executed a major deleveraging initiative, cutting debt from $68M to $23M while preserving cash generation capabilities and improving equity position by over 40%. However, the substantial decline in cash reserves from $69M to $30M suggests this debt reduction may have consumed significant liquidity, creating a trade-off between financial flexibility and leverage reduction.

Comparing 2026-02-26 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

PBYI's financial profile improved meaningfully with debt declining substantially from $68M to $23M and stockholders' equity growing 42% to $130M, while operating income increased 20% to $37M. The company reduced R&D spending by 26% to $72M and saw accounts receivable grow notably to $54M, suggesting stronger sales activity. However, cash reserves dropped significantly from $69M to $30M, indicating the debt reduction strategy consumed considerable liquidity, though the overall deleveraging and maintained profitability present a stronger capital structure.

FINANCIAL STATEMENT CHANGES
Accounts Receivable
Balance Sheet
+67.6%
$32.0M→$53.7M

Receivables surged 67.6% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Total Debt
Balance Sheet
-66.7%
$68.0M→$22.7M

Debt reduced 66.7% — deleveraging strengthens balance sheet and reduces financial risk.

Cash & Equivalents
Balance Sheet
-57.2%
$69.2M→$29.6M

Cash declined 57.2% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Stockholders Equity
Balance Sheet
+41.5%
$92.1M→$130.3M

Equity base grew 41.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Inventory
Balance Sheet
-36.8%
$8.7M→$5.5M

Inventory drawn down 36.8% — strong sell-through or deliberate destocking; watch for supply constraints.

Total Liabilities
Balance Sheet
-29.1%
$121.2M→$86.0M

Liabilities reduced 29.1% — deleveraging improves balance sheet strength and financial flexibility.

Capital Expenditure
Cash Flow
+26.8%
$56K→$71K

Capex increased 26.8% — ongoing investment in capacity or infrastructure for future growth.

R&D Expense
P&L
-26.4%
$97.7M→$71.9M

R&D spending cut 26.4% — could signal cost discipline or concerning reduction in innovation investment.

Operating Income
P&L
+20.5%
$31.0M→$37.3M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Current Liabilities
Balance Sheet
-15.5%
$96.1M→$81.3M

Current liabilities reduced — improved short-term financial position and working capital health.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-27
ADDED
false --12-31 FY 2025 true true true false true true false false false false true 0 362 0.0001 0.0001 100,000,000 100,000,000 50,408,023 50,408,023 49,105,834 49,105,834 5 10.6 4 4 15.2 2.1 3 3 7 0 9.7 9.7 9.7 0.4 0.4 5.417 5 5 2.0 0 3 1.6 1.6 14.9 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 State taxes in Kentucky and Indiana comprise the majority (greater than 50%) of the tax effect in this category.
Other research and development expense include regulatory affairs, pharmacovigilance, quality assurance, chemical manufacturing and other costs.
As of February 23, 2026, there were 50,876,487 shar es of the registrant s common stock outstanding.
These risks include, among others, the following: While we have reported net income in recent years, we cannot assure that we will continue to do so and may not be able to maintain profitability.
We are currently commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers.
+7 more — sign up free →
REMOVED
false --12-31 FY 2024 true true true false true true false false false false 362 881 0.0001 0.0001 100,000,000 100,000,000 49,105,834 49,105,834 47,646,787 47,646,787 0 0 0 200 4 2.1 3 3 7 9.7 9.7 9.7 9.7 5 4.9 4.9 2 2,000 0 0 3 Other research and development expense include regulatory affairs, pharmacovigilance, quality assurance, chemical manufacturing and other costs.
As of February 24, 2025 , there were 49,610,799 shar es of the registrant s common stock outstanding.
These risks include, among others, the following: While we have reported net income in the years ended December 31, 2024, 2023 and 2022, we cannot assure that we will continue to do so and may not be able to maintain profitability.
We are currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer.
Based on information in this database, we believe alisertib has potential application in the treatment of range of different cancer types, including hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer and head and neck cancer.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →